Navigation Links
Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
Date:12/11/2007

Three-fold Lower Incidence of Severe Cardiac Toxicity With Equivalent

Complete Remission Rates Reported

ATLANTA, Dec. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced today that preliminary data from its phase II/III randomized study comparing CPOP-R to CHOP-R in the first-line treatment of patients with aggressive non-Hodgkin's lymphoma (NHL) showed patients who received pixantrone experienced less severe (grade 3/4) toxicities including severe infection and febrile neutropenia when compared to patients treated with standard doxorubicin-based therapy. A preliminary analysis of the study, known as PIX203, which is ongoing, was presented at the American Society of Hematology (ASH) Annual Meeting in Atlanta.

"While preliminary, these randomized trial results are encouraging in supporting the preclinical findings that pixantrone is associated with a lower incidence of severe cardiac damage as evidenced by substantial declines in ejection fraction than standard anthracylines such as doxorubicin when administered as part of combination chemotherapy in the front line treatment of aggressive NHL," said Jack W. Singer, Chief Medical Officer of CTI. "Although preliminary, these data suggest that there may be reductions in other clinically important toxicities such as febrile neutropenia and severe infections without a loss in anti-tumor activity. These findings, along with its robust preclinical profile, suggest that pixantrone is an ideal drug candidate for further investigation in clinical trials for NHL, breast cancer and other diseases where anthracyclines are standard of care."

CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) Compared to CPOP-R (cyclophosphamide, pixantrone, vincristine, prednisone, rituximab) in 1st Line Therapy of Diffuse Large B cell Lymphoma (DLBCL): An Interim Analysis

Data were presented that show CPOP-R had comparable ant
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Review of Probiotic Trial Research Finds Only Bifantis(R) Able to Claim Efficacy versus Placebo for IBS Symptoms
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. Progesterone Therapy and Preterm Birth: More Evidence Helps Identify Women Who Can Benefit
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
8. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
9. St. Jude Discovers Factors That Accelerate Resistance to Gleevec(TM) Targeted Therapy in Lymphoblastic Leukemia
10. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
11. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)...paign to Spread Awareness and Bring Hope to Millio...swire-USNewswire/ -- 133 million children,across t...uch as natural,disaster, civil war, and disease. S...World Orphan Week by calling attention to the need...ews Release, go to:, http://www.prnewswire.com/m...
(Date:10/9/2008)...nal Science Institute, Navigenics, Affymetrix and,...N DIEGO, Oct. 9 /- A consortium of he...ined forces in a first-of-its-kind,research study ...c testing,on people who choose to receive such scr...oping certain diseases., Sponsored by Scripps Tra...
(Date:10/8/2008)...eday Inform Treatments for Spinal Cord, Other Nerv...Newswire/ -- A protein that enables,nerve cells to...ontrolling,the developing nervous system. Research...o form among nerve cells may provide a basis for e...s to their nervous system,including spinal cord i...
(Date:10/8/2008)...am to evaluate TAXUS(R) Element(TM) Platinum Chrom..., Mass., Oct. 8 /- Boston S...d that it has completed enrollment in,the PERSEUS ...neration,TAXUS(R) Element(TM) paclitaxel-eluting c...rolled nearly 1,500 patients at 100 U.S. and,inter...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4Your belly fat could be making you hungrier 17023 1Your belly fat could be making you hungrier 17023 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 1GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 2GHX Introduces NuVia 28TM 29 an Artificial Intelligence based Technology That Enables a New Approach to Content Management for Healthcare Providers 17020 3The Miracle of Funding by State and Local Pension Plans 17016 1The Miracle of Funding by State and Local Pension Plans 17016 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 1AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 2AegisLiving Partners With Technogym USA to Enhance Wellness Throughout Its Communities 17012 3
...WIRE)--Jun 1, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, ...mpany developing novel therapeutics to treat cance...n of two abstracts in the,2007 Annual Meeting prog...ng of the American Society of Clinical Oncology (A...or the first time full data from a,randomized Phas...
... 2007 /PRNewswire-FirstCall/ -- Kosan,Biosciences ...se 2,monotherapy trial showing that tanespimycin d... patients with metastatic melanoma,including one ...d,prior chemotherapy (within 6 weeks of initiation...on-free survival for more than,six months and 20% ...
Other Medicine Technology:OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 2Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 3Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity,of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO 4
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall/...loper, manufacturer and supplier of premium,diagno...ts dedicated to,serving the healthcare needs of wo...uarter and fiscal 2008 operating results on Tuesda...ction with the release, management will,host a con...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVie... management of Trace Life Sciences Inc.,(Trace), i...cyclotron,production facilities in Denton, Texas. ... Indium-111, Iodine-123 and Thallium-201 used in,m... NuView Chairman and,CEO, stated that "We are conf...
(Date:10/10/2008)... Coach Holly Warlick Teams Up with Legal and Me...rst-Ever Cancer and Careers Seminar in,Knoxville, ...gnition of National,Breast Cancer Awareness Month,... have joined forces with YWCA Knoxville, The Welln...ocate Holly Warlick, University of Tennessee,women...
(Date:10/10/2008)... The Healthcare Technolog...Care , Exton, PA (PRWEB) ...Valley Chapters of the national Healthcare Informa...ned forces to bring regional health information te...onal conference entitled The Healthcare Technology...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2
...test mysteries that has been plaguing mankind is t... have finally been able to unravel the mystery wit...y scientists after a study of more than 1000 peopl...eed to be answered on a scale of 1 to 10 and the s...
...by researchers in the Institute of Preventive Medi...asionally may be beneficial in countering dementia...that people who drank wine weekly or monthly were ...ia, said that the findings are important because t...
...earchers of the Harvard Medical School, of more th...amine antagonists, i.e. anti-psychotics, for eithe... have an increased risk of breast cancer. The stud... taking dopamine antagonists and 55,000 women who ...
...ished in an online issue of Nature Medicine by res... a stunning discovery of a bold new type of vaccin...gs. The study which was carried// out on monkeys s...med and adapted in humans may signal a major new t...
Other Medicine News:Health News:The Happiness Formula.... 2
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: